Armistice Capital LLC Boosts Position in BridgeBio Oncology Therapeutics, Inc $BBOT - American Market News
Author: ABMN Staff
Description: Read Armistice Capital LLC Boosts Position in BridgeBio Oncology Therapeutics, Inc $BBOT at American Market News
Keywords: BridgeBio Oncology Therapeutics,NASDAQ:BBOT,BBOT,Financial Service,SEC Filings,13F,Hedge Fund Holdings,Institutional Investor Holdings
Date: 2026-06-18T08:25:47+0000

Skip to main content

# Armistice Capital LLC Boosts Position in BridgeBio Oncology Therapeutics, Inc $BBOT

Posted by ABMN Staff on Jun 18th, 2026

Share on Twitter
Share on Facebook
Share on LinkedIn
Share on Stocktwits

Armistice Capital LLC raised its position in BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT – Free Report) by 142.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,000,000 shares of the company’s stock after acquiring an additional 588,000 shares during the quarter. Armistice Capital LLC owned approximately 1.25% of BridgeBio Oncology Therapeutics worth $12,520,000 at the end of the most recent quarter.

Get BridgeBio Oncology Therapeutics alerts:

A number of other large investors have also made changes to their positions in BBOT. CIBC Private Wealth Group LLC purchased a new position in shares of BridgeBio Oncology Therapeutics in the fourth quarter worth approximately $63,000. Persistent Asset Partners Ltd purchased a new stake in BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics in the fourth quarter worth approximately $144,000. BIT Capital GmbH purchased a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $313,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth $670,000. 54.89% of the stock is currently owned by institutional investors.

## Wall Street Analysts Forecast Growth

BBOT has been the subject of several analyst reports. HC Wainwright upped their price objective on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Wall Street Zen downgraded BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Canaccord Genuity Group assumed coverage on BridgeBio Oncology Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $23.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Check Out Our Latest Stock Analysis on BBOT

## BridgeBio Oncology Therapeutics Stock Performance

NASDAQ BBOT opened at $7.68 on Thursday. The company has a market capitalization of $615.24 million, a price-to-earnings ratio of -3.75 and a beta of 0.29. The stock has a 50-day simple moving average of $8.43. BridgeBio Oncology Therapeutics, Inc has a twelve month low of $7.00 and a twelve month high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that BridgeBio Oncology Therapeutics, Inc will post -2.32 earnings per share for the current fiscal year.

## BridgeBio Oncology Therapeutics Company Profile

(Free Report)

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.

## See Also

- Five stocks we like better than BridgeBio Oncology Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?

Want to see what other hedge funds are holding BBOT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT – Free Report).

Receive News & Ratings for BridgeBio Oncology Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Oncology Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

## You might be interested in:

Armistice Capital LLC Acquires 42,476 Shares of Datadog, Inc. $DDOG
BNB Wealth Management LLC Buys New Shares in Netflix, Inc. $NFLX
Bamco Inc. NY Boosts Stock Position in Amazon.com, Inc. $AMZN
American Trust Sells 3,680 Shares of Apple Inc. $AAPL
18,087 Shares in Amazon.com, Inc. $AMZN Purchased by BNB Wealth Management LLC
Armistice Capital LLC Has $84.86 Million Stake in Amazon.com, Inc. $AMZN